Bristol Myers Squibb Co., based in Princeton, NJ, employs 34,100 staff and develops biopharmaceuticals across various therapeutic classes, including oncology and immunology. Key products include Eliquis and Opdivo, with a strong pipeline featuring Krazati and KarXT.
BMY has been in the news recently: Bristol Myers Squibb has formed a multibillion-dollar co-development agreement with BioNTech to advance cancer therapy BNT327, despite its stock declining 18% this year. The collaboration aims to enhance their drug development efforts in the oncology field.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
